Clinical Trial: Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Development of Novel Therapeutics for AMKL
Brief Summary:
RATIONALE: Studying samples of blood or tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in samples from patients with Down syndrome and acute megakaryoblastic leukemia.
Detailed Summary:
OBJECTIVES:
- Determine whether megakaryocyte differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor can lead to proliferation arrest, polyploidization, and terminal differentiation of blasts in specimens from patients with Down syndrome and acute megakaryoblastic leukemia.
OUTLINE: Cryopreserved specimens are cultured and treated in vivo (in mice) and in vitro with megakaryocytic differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor.
Sponsor: Children's Oncology Group
Current Primary Outcome:
- Proliferation arrest
- Polyploidization
- Terminal differentiation
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Children's Oncology Group
Dates:
Date Received: June 5, 2010
Date Started: July 2009
Date Completion:
Last Updated: February 19, 2016
Last Verified: February 2016
